Temporal lobe epilepsy with isolated amygdala enlargement: anatomo-electro-clinical features and long-term outcome.

Background: Temporal lobe epilepsy with isolated amygdala enlargement (TLE-AE) still lacks a definite characterization and controversies exist.

Methods: We conducted a retrospective study identifying brain MRI scans with isolated AE between 2015 and 2021. We collected clinical and paraclinical data of patients with TLE-AE and evaluated the outcome.

Understanding how cardiorespiratory training is implemented to address cardiorespiratory fitness in adults following a stroke: a systematic review.

Purpose: To systematically review the evidence investigating the implementation of cardiorespiratory (CR) training in adults following a stroke and to understand how interventions are prescribed to address cardiorespiratory fitness (CRF).

Methods: Medline, CINAHL, EMBASE, EMCARE, Scopus, PEDro and ProQuest were searched from inception until January 2024. Inclusion criteria were studies that included adults following a stroke, investigated CR training interventions and used standardised CRF assessments.

sp. nov., a Gram-Positive, Spore-Forming Rod Isolated from a Pharmaceutical Facility Production Environment and Added to the MALDI Biotyper Database.

A Gram-positive, aerobic, rod-shaped and spore-forming bacterium strain designation, B190/17, was isolated from an air monitoring sample of a Brazilian immunobiological production facility in 2017. The strain was not identifiable by biochemical methodology VITEK 2 or by MALDI-TOF MS with VITEK MS RUO and MALDI Biotyper. The 16S rRNA gene sequencing results showed 98.

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.

Patients diagnosed with metastatic colorectal cancer (mCRC) have a poor prognosis with survival ranging 2-3 years. The prevalence of human epidermal growth factor receptor 2 (HER2) amplification is approximately 3-4% in mCRC and increases up to 8% in patients with // wild-type (WT) CRC tumors. Tucatinib is a highly selective HER2-directed tyrosine kinase inhibitor that, in combination with trastuzumab, has demonstrated clinically meaningful activity in patients with chemotherapy-refractory, HER2-positive (HER2+), WT mCRC in the MOUNTAINEER trial.